Provides data analytics solutions for healthcare cost management. Offers technology-enabled payment and revenue integrity services. Now — the numbers.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

This company is not turning a profit, so the market is pricing its sales instead: 0.6× for every dollar of annual revenue.

Against companies in its own sector, it looks cheaper than 43% of them.

Analysts' average target sits 45% above today's price.

We compared this company with its own sector across five subjects.

A score of 50 means class average.

Clearly above the class average — a step short of the very top.

Clearly below the class average.

Clearly below the class average.

This grade is a blend: the profit side is strong, the sales tempo slow.

Clearly above the class average — a step short of the very top.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

On our five-subject report card, CTEV sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: CTEV’s sales are going backwards, and it closed last year at a loss. The road back runs through both.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (43/100) says the stock isn’t cheap.

Not covered, because the filings we hold do not carry it: the revenue breakdown.